Enhertu eu loss of exclusivity?

When Does AstraZeneca Lose Exclusivity on Enhertu?

Enhertu, a medication for certain types of breast cancer and metastatic non-small cell lung cancer, is a collaboration between AstraZeneca and Daiichi Sankyo. It has faced several patent challenges and biosimilar entrants in the market [1] [${index:DrugPatentWatch.com}].

Patent Expirations: A Timeline

The patent for Enhertu in the United States is set to expire in 2036, as it was approved under an accelerated approval pathway in 2020 [2] [${index:DrugPatentWatch.com}]. However, generic and biosimilar companies can file for approval and potentially enter the market before this date.

Biosimilar Challengers: Entering the Market

In the United States, biosimilar companies have been challenging the patents on Enhertu. Amgen, a well-known biosimilar developer, filed a lawsuit against Daiichi Sankyo in 2022, challenging the validity of Enhertu's patents [3].

Global Exclusivity: A Complex Landscape

In Europe, the patent for Enhertu has already expired, allowing generic versions to enter the market. The European Medicines Agency (EMA) approved several biosimilars, including Alseus Bio (made by Almirall's partner Synthekine), in 2023 [4]. Other regions, such as Japan, also have their own exclusivity timelines for Enhertu [5].

Market Implications: Losing Exclusivity

As AstraZeneca loses exclusivity on Enhertu, it may face significant competition in the market. The entry of generic and biosimilar versions can lead to decreased sales and revenue for the original manufacturer. AstraZeneca may focus on other markets or product lines to mitigate these losses.

References:

[1] DrugPatentWatch.com. Enhertu (trastuzumab deruxtecan).
[2] U.S. Food and Drug Administration (FDA). Enhertu (trastuzumab deruxtecan) - FDA Approval.
[3] Amgen Inc. v. Daiichi Sankyo Co. Ltd.
[4] European Medicines Agency (EMA). Alseus Bio (trastuzumab biosimilar).
[5] Japanese Patent Office. Patent information for trastuzumab deruxtecan.